Lv1
30 积分 2024-03-29 加入
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
8个月前
已完结
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
8个月前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
9个月前
已完结
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
9个月前
已完结
Risk factors and management strategies associated with non-response to aminosalicylates for maintenance treatment in ulcerative colitis
10个月前
已完结
Sa1675: PLACEBO EFFECTS ACROSS THERAPIES IN DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
11个月前
已完结
Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis
11个月前
已完结
Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
11个月前
已完结
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
11个月前
已完结
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
11个月前
已完结